Ocumetrics Technology Corp. (TSXV: OTC; OTCQB: OTCFF; FRA: 2QBO) has reported highly encouraging six-month postoperative results from the first group of patients in its first-in-human (FIH) clinical study of the Ocumetrics Accommodating Intraocular Lens ("Ocumetrics Lens"). The outcomes exceeded the company's expectations, demonstrating continued vision improvements and a strong safety profile, alongside anecdotal reports of life-changing impacts on patients' daily lives.
Patients in Group One entered the study with severely impaired vision, including one individual considered legally blind. Six months after surgery, all patients showed stable visual acuity and ongoing improvement, with many now able to read, drive, and live independently. "What stands out most is not just the clinical performance of the Ocumetrics Lens, but the profound impact on patients' quality of life," said Dean Burns, President and CEO of Ocumetrics. "We're developing a technology that dramatically improves people's quality of life."
The results validate the company's technology and provide momentum for the next phase of the clinical program. Ocumetrics is incorporating surgeon feedback and patient experience into ongoing product enhancements, with updated lens refinements currently in manufacturing and testing. These refinements support the planned initiation of Group Two surgeries. "The measurable improvements in visual acuity and consistency we are seeing at six months give us tremendous confidence as we advance," added Burns.
The Ocumetrics Lens is a dynamic intraocular lens designed to fit within the eye's natural lens compartment, potentially eliminating the need for corrective lenses. It uses the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without perceptible time lag. The company's first-in-human study is an early feasibility study for this innovative technology.
Ocumetrics will host a webinar on April 22, 2026, at 4:00 PM ET to discuss the six-month results and provide updates on the FIH study. Registration is available at www.ocumetics.com/webinar.
The company's forward momentum continues as it aims to transform vision correction. The positive six-month results underscore the potential of the Ocumetrics Lens to address significant unmet needs in ophthalmology, particularly for patients with severe vision impairment. As the company advances toward Group Two surgeries, the focus remains on optimizing performance and bringing this life-changing solution to more patients.
